CHENGDU KANGHONG PHARMACEUTICAL GROUP CO., LTD

Chengdu Kanghong Pharmaceutical Group Co., Ltd

002773

CNE1000020C4

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 18:00:00 2024-06-27 EDT			5-day change	1st Jan Change
21.65 ^CNY	-0.46%		-3.05%	+17.41%

06-19	Kanghong Pharmaceutical's Unit Gets Nod to Market Conbercept Eye Injection in Myanmar	MT
06-04	Kanghong Pharmaceutical Gets Regulatory Nod for Pranoprofen Eye Drop	MT

Chengdu Kanghong Pharmaceuticals Group Co., Ltd Announces Executive Changes

December 30, 2019 at 09:32 am

Chengdu Kanghong Pharmaceuticals Group Co. Ltd. announced executive changes. Zhang Qiang, Qu Sancai and Zhang Yu have been elected as independent directors. Yin Jinqun and CHEN SU have been elected as non-independent directors in the Extraordinary General Meeting of 2019 on December 27, 2019.

Latest news about Chengdu Kanghong Pharmaceutical Group Co., Ltd

Kanghong Pharmaceutical's Unit Gets Nod to Market Conbercept Eye Injection in Myanmar	06-18	MT
Kanghong Pharmaceutical Gets Regulatory Nod for Pranoprofen Eye Drop	06-03	MT
Chengdu Kanghong Pharmaceutical Group Co., Ltd Announces Final Cash Dividend on A Shares for the Year 2023, Payable on 28 May 2024	05-21	CI
Kanghong Pharmaceutical's Unit Gets US FDA's Green Light to Test Macular Degeneration Drug	04-29	MT
Kanghong Pharmaceutical's Unit Gets Nod to Trial Macular Degeneration Drug	04-29	MT
Chengdu Kanghong Pharmaceutical Group Co., Ltd Proposes Final Cash Dividend for the Year 2023	04-24	CI
Chengdu Kanghong Pharmaceutical Group Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024	04-24	CI
Chengdu Kanghong Pharmaceutical Group Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	04-24	CI
Kanghong Pharmaceutical's Mosapride Citrate Tablets Wins Centralized Procurement Bid	04-17	MT
Kanghong Pharmaceutical's Beijing Unit Gets China's Approval for Clinical Trials for Anti-Tumor Injection	03-06	MT
Kanghong Pharmaceutical's Unit Gets Nod to Trial Psoriasis Drug	02-27	MT
Kanghong Pharmaceutical Gets Nod for Registration of Escitalopram Oxalate Tablets	12-12	MT
Kanghong Pharma's Aripiprazole Oral Solution Chosen for China's Centralized Drug Procurement	11-08	MT
Kanghong Pharma Gets FDA Nod to Trial Drug Against Fatty Liver Disease	11-06	MT
Chengdu Kanghong Pharmaceutical Group Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-26	CI
Kanghong Pharmaceutical Gets US FDA's Clinical Trial Nod for Antidepressant	23-10-24	MT
Chengdu Kanghong Pharmaceutical Group Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-27	CI
Chengdu Kanghong Pharmaceutical Group Co., Ltd Announces Executive Changes	23-08-04	CI
Kanghong Pharma Gets Nod to Trial Antidepressant	23-07-20	MT
Chengdu Hongji Biotechnology Co., Ltd. announced that it expects to receive CNY 159.736344 million in funding from Chengdu Kanghong Pharmaceutical Group Co., Ltd, Chengdu Kangji Enterprise Management Consulting Partnership (Limited Partnership), Chengdu Kangyin Enterprise Management Consulting Partnership (Limited Partnership), Chengdu Kangzhi Technology Consulting Partnership (Limited Partnership)	23-07-11	CI
Kanghong Pharma Gets Continued Protection for Traditional Chinese Medicine	23-06-20	MT
Chengdu Kanghong Pharmaceutical Group Co., Ltd Announces Final Cash Dividend on Share A for 2022, Payable on June 6, 2023	23-05-30	CI
Chengdu Kanghong Pharmaceutical Group Co., Ltd Approves Cash Dividend for the Year 2022	23-05-24	CI
Chengdu Kanghong Pharmaceutical Group Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-27	CI
Chengdu Kanghong Pharma Wins Orphan Drug Designation in US	23-02-16	MT

Chart Chengdu Kanghong Pharmaceutical Group Co., Ltd

Duration

Period

Chart Chengdu Kanghong Pharmaceutical Group Co., Ltd

More charts

Company Profile

Chengdu Kanghong Pharmaceutical Group Co., Ltd is a China-based company principally engaged in the research, development, manufacture and distribution of Chinese patent medicines, chemical drugs and biological products. The Companyâs main products include Conbercept Ophthalmic Injection, Songling capsules conducive to blood vessels, Keluoxin capsules, venlafaxine hydrochloride capsules and sustained release tablets, aripiprazole tablets and orally disintegrating tablets, mosapride citrate tablets and dispersible tablets, dexzopiclone tablets, Shuganjieyu capsules, Danshu capsules and Yiqing capsules, among others. The Company distributes its products in domestic market.

Sector

Pharmaceuticals

Calendar

2024-08-25 - Q2 2024 Earnings Release (Projected)

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
CHENGDU KANGHONG PHARMACEUTICAL GROUP CO., LTD	+17.41%	2.74B
ELI LILLY AND COMPANY	+55.32%	815B
JOHNSON & JOHNSON	-6.75%	352B
MERCK & CO., INC.	+13.56%	314B
ABBVIE INC.	+10.68%	303B
ASTRAZENECA PLC	+16.57%	242B
ROCHE HOLDING AG	+2.04%	224B
NOVARTIS AG	+13.31%	218B
AMGEN INC.	+8.48%	168B
PFIZER, INC.	-2.81%	159B

Other Pharmaceuticals

Chengdu Kanghong Pharmaceutical Group Co., Ltd

Equities

002773

CNE1000020C4

Pharmaceuticals

Chengdu Kanghong Pharmaceuticals Group Co., Ltd Announces Executive Changes

Latest news about Chengdu Kanghong Pharmaceutical Group Co., Ltd

Chart Chengdu Kanghong Pharmaceutical Group Co., Ltd

Company Profile

Income Statement Evolution

EPS Revisions

Annual profits - Rate of surprise

Sector Other Pharmaceuticals